loading

Dechra Pharmaceuticals PLC
Search Trigger Search Trigger
  • Strategic Report
    • Welcome to Dechra Pharmaceuticals PLC
    • Delivering Consistently for Our Shareholders
    • Continuing Our Growth Story
    • Highlights
    • Our Business Model
    • Our Products
    • Dechra Values
    • Delivering Our Strategy
    • Geographical Footprint
    • Non-Executive Chairman's and Chief Executive Officer's Statement
    • Financial Review
    • Q&A with Ian Page
    • Q&A with Richard Cotton
    • Key Performance Indicators
    • Strategy in Action
    • Strategic Enablers
    • Product Development
    • International Product Offering
    • Corporate Social Responsibility
    • How the Business Manages Risk
    • Understanding Our Key Risks
  • Governance
    • Board of Directors
    • Letter from the Chairman on Governance
    • Corporate Governance
    • Letter from the Audit Committee Chairman
    • Audit Committee Report
    • Nomination Committee Report
    • Letter from the Remuneration Committee Chairman
    • Directors' Remuneration Report
    • Directors' Report - Other Disclosures
    • Statement of Directors' Responsibilities
  • Financial Statements
    • Independent Auditor's Report to the Members of Dechra Pharmaceuticals PLC
    • Consolidated Income Statement
    • Consolidated Statement of Comprehensive Income
    • Consolidated Statement of Financial Position
    • Consolidated Statement of Changes in Shareholders' Equity
    • Consolidated Statement of Cash Flows
    • Notes to the Consolidated Financial Statements
    • Company Statement of Financial Position
    • Company Statement of Changes in Shareholders' Equity
    • Notes to the Company Financial Statements
    • Financial History
  • Shareholder Information
    • Shareholder Information
    • Advisers
    • Glossary

Annual Report and Accounts for the Year Ended 30 June 2017

Horse Running
Pdf

Notes to the Consolidated Financial Statements

  • Home
  • Financial Statements
  • Notes to the Consolidated Financial Statements

Notes to the Consolidated Financial Statements

Cookies This website uses cookies. Read our cookie policy for further details.

  • 1. Accounting Policies
  • 2. Operating Segments
  • 3. Finance Income
  • 4. Finance Expense
  • 5. Non-underlying Items
  • 6. Interests in Associate
  • 7. Profit Before Taxation
  • 8. Employees
  • 9. Income Tax Expense
  • 10. Dividends
  • 11. Earnings per Share
  • 12. Intangible Assets
  • 13. Property, Plant and Equipment
  • 14. Impairment Reviews
  • 15. Deferred Taxes
  • 16. Inventories
  • 17. Trade and Other Receivables
  • 18. Cash and Cash Equivalents
  • 19. Trade and Other Payables
  • 20. Current Tax Liabilities
  • 21. Borrowings
  • 22. Provisions
  • 23. Employee Benefit Obligations
  • 24. Financial Instruments and Related Disclosures
  • 25. Share Capital
  • 26. Own Shares
  • 27. Non-Controlling Interests
  • 28. Share-based Payments
  • 29. Analysis of Net Borrowings
  • 30. Operating Leases
  • 31. Foreign Exchange Rates
  • 32. Acquisitions
  • 33. Related Party Transactions
  • 34. Off Balance Sheet Arrangements
  • 35. Events after the Reporting Period
  • Page Previous Navigation Page Previous Navigation prev Consolidated Statement of Cash Flows
  • Page Next Navigation Page Next Navigation next 1. Accounting Policies
Top

Site Essentials

  • Site Map
  • Accessibility
  • Cookies

Designed & developed by
Jones and Palmer

© 2017 Dechra Pharmaceuticals PLC

www.dechra.com